|
Hypertensive disease
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Subgroup genetic mappings uncovered additional shared synaptic genes, including CAMK4, CNTN5 and DNM3 (hypertension-specific); CNTN4, DNM3, FHIT and ITPR1 (sex-specific), having protein interactions with genes driven from general analysis.
|
22297481 |
2012 |
|
Paraganglioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas.
|
28938490 |
2018 |
|
Pheochromocytoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas.
|
28938490 |
2018 |
|
Benign Neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Contactin 4 (CNTN4) was overexpressed in malignant vs benign tumors [4.62-fold; false discovery rate (FDR), 0.001].
|
28938490 |
2018 |
|
Adrenal Gland Pheochromocytoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas.
|
28938490 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Mutation and gene expression analyses of well-defined EOC cell lines (OV-90, TOV-112D, TOV-21G, and TOV-81D) that differ in their tumorigenic potential and chromosome 3p26-pter genomic content revealed CNTN4 expression and a novel mutation only in the tumorigenic EOC cell line TOV-21G.
|
19509545 |
2009 |
|
Autistic Disorder
|
0.340 |
Biomarker
|
disease |
BEFREE |
Thus, additional larger studies will be necessary to determine whether CNTN4 functions as an autism susceptibility locus in combination with other genetic and/or environmental factors.
|
21308999 |
2011 |
|
Autistic Disorder
|
0.340 |
Biomarker
|
disease |
BEFREE |
The contactin (CNTN) family of Ig cell adhesion molecules (IgCAMs) harbours at least three members that have genetically been implicated in autism: CNTN4, CNTN5, and CNTN6.
|
23872404 |
2013 |
|
Autistic Disorder
|
0.340 |
Biomarker
|
disease |
CTD_human |
Disruption of contactin 4 in three subjects with autism spectrum disorder.
|
18349135 |
2009 |
|
Alcoholic Intoxication, Chronic
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Bipolar disorder with alcohol dependence and other co-morbidities was associated with SNP rs2727943 (p = 3.3×10⁻⁸) on chromosome 3p26.3 located between the genes contactin-4 precursor (BIG-2) and contactin 6 (CNTN6).
|
22205951 |
2011 |
|
Bipolar Disorder
|
0.300 |
Biomarker
|
disease |
PSYGENET |
Bipolar disorder with alcohol dependence and other co-morbidities was associated with SNP rs2727943 (p = 3.3×10⁻⁸) on chromosome 3p26.3 located between the genes contactin-4 precursor (BIG-2) and contactin 6 (CNTN6).
|
22205951 |
2011 |
|
Developmental Disabilities
|
0.300 |
Biomarker
|
group |
CTD_human |
Disruption of contactin 4 (CNTN4) results in developmental delay and other features of 3p deletion syndrome.
|
15106122 |
2004 |
|
Growth Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Disruption of contactin 4 (CNTN4) results in developmental delay and other features of 3p deletion syndrome.
|
15106122 |
2004 |
|
Child Development Deviations
|
0.300 |
Biomarker
|
disease |
CTD_human |
Disruption of contactin 4 (CNTN4) results in developmental delay and other features of 3p deletion syndrome.
|
15106122 |
2004 |
|
Child Development Disorders, Specific
|
0.300 |
Biomarker
|
disease |
CTD_human |
Disruption of contactin 4 (CNTN4) results in developmental delay and other features of 3p deletion syndrome.
|
15106122 |
2004 |
|
Craniofacial Abnormalities
|
0.300 |
Biomarker
|
group |
CTD_human |
Disruption of contactin 4 (CNTN4) results in developmental delay and other features of 3p deletion syndrome.
|
15106122 |
2004 |
|
Autism Spectrum Disorders
|
0.070 |
Biomarker
|
disease |
BEFREE |
Deletions and duplications involving the CNTN4 gene, which encodes for the contactin 4 protein, have been reported in children with autism spectrum disorder (ASD) and other neurodevelopmental phenotypes.
|
31422286 |
2020 |
|
Autism Spectrum Disorders
|
0.070 |
Biomarker
|
disease |
BEFREE |
Recent genetic studies of neuropsychiatric disorders have pinpointed contactin-4 (CNTN4), contactin-5 (CNTN5) and contactin-6 (CNTN6) as candidate genes in neurodevelopmental disorders, particularly in autism spectrum disorders (ASDs), but also in intellectual disability, schizophrenia (SCZ), attention-deficit hyperactivity disorder (ADHD), bipolar disorder (BD), alcohol use disorder (AUD) and anorexia nervosa (AN).
|
28064060 |
2017 |
|
Autism Spectrum Disorders
|
0.070 |
Biomarker
|
disease |
BEFREE |
In this study, we used mutant/knock-out mice of Shank2 (<i>Shank2</i><sup>-/-</sup>), Shank3 (<i>Shank3</i>αβ<sup>-/-</sup>), and Cntn4 (<i>Cntn4</i><sup>-/-</sup>) as ASD-models to explore whether these mice share a molecular signature in glutamatergic and GABAergic synaptic transmission in ASD-related brain regions.
|
29970989 |
2018 |
|
Autism Spectrum Disorders
|
0.070 |
Biomarker
|
disease |
BEFREE |
Disruption of contactin 4 in three subjects with autism spectrum disorder.
|
18349135 |
2009 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
|
30335191 |
2019 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.
|
31134488 |
2019 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.
|
29207087 |
2018 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.
|
31134488 |
2019 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.
|
29207087 |
2018 |